Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan J Clark

Showing results (121-130 of 142) with videos related to

Pageof 15
Sort By:
BJU International|August 5, 2024
Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation - IRE-IMMUNO studyBart Geboers, Matthijs J Scheltema, Jason Jung, et al.
Epigenetics & Chromatin|May 30, 2018
Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X TenShalima S Nair, Phuc-Loi Luu, Wenjia Qu, et al.
Molecular Cancer|March 27, 2025
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trialDarren Korbie, Clare Stirzaker, Oleg Gluz, et al.
Cancers|December 16, 2020
Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia PatientsUlf Schmitz, Jaynish S Shah, Bijay P Dhungel, et al.
Biomaterials|April 9, 2013
A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancerAshlee K Clark, Anna V Taubenberger, Renea A Taylor, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 25, 2010
Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkersJames Devaney, Clare Stirzaker, Wenjia Qu, et al.
Oncogene|July 27, 2025
PPARγ acetylation governs mammary adenocarcinoma tumor growth via acetylated residues that determine DNA sequence-specific bindingLifeng Tian, Xuanmao Jiao, Chenguang Wang, et al.
Human Molecular Genetics|July 6, 2016
Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancerMichael J G Milevskiy, Fares Al-Ejeh, Jodi M Saunus, et al.
Nature Communications|January 18, 2020
Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancerJoanna Achinger-Kawecka, Fatima Valdes-Mora, Phuc-Loi Luu, et al.
Nature Communications|November 9, 2017
Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancerFátima Valdés-Mora, Cathryn M Gould, Yolanda Colino-Sanguino, et al.
Pageof 15

Showing results (121-130 of 142) with videos related to

Sort By:
Pageof 15
BJU International|August 5, 2024
Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation - IRE-IMMUNO studyBart Geboers, Matthijs J Scheltema, Jason Jung, et al.
Epigenetics & Chromatin|May 30, 2018
Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X TenShalima S Nair, Phuc-Loi Luu, Wenjia Qu, et al.
Molecular Cancer|March 27, 2025
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trialDarren Korbie, Clare Stirzaker, Oleg Gluz, et al.
Cancers|December 16, 2020
Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia PatientsUlf Schmitz, Jaynish S Shah, Bijay P Dhungel, et al.
Biomaterials|April 9, 2013
A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancerAshlee K Clark, Anna V Taubenberger, Renea A Taylor, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 25, 2010
Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkersJames Devaney, Clare Stirzaker, Wenjia Qu, et al.
Oncogene|July 27, 2025
PPARγ acetylation governs mammary adenocarcinoma tumor growth via acetylated residues that determine DNA sequence-specific bindingLifeng Tian, Xuanmao Jiao, Chenguang Wang, et al.
Human Molecular Genetics|July 6, 2016
Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancerMichael J G Milevskiy, Fares Al-Ejeh, Jodi M Saunus, et al.
Nature Communications|January 18, 2020
Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancerJoanna Achinger-Kawecka, Fatima Valdes-Mora, Phuc-Loi Luu, et al.
Nature Communications|November 9, 2017
Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancerFátima Valdés-Mora, Cathryn M Gould, Yolanda Colino-Sanguino, et al.
Pageof 15